Close

Gilead Sciences (GILD) Receives EC Marketing Approval for Sovaldi as CHC Treatment

January 17, 2014 9:11 AM EST Send to a Friend
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the European Commission has granted marketing authorization for SovaldiĀ® (sofosbuvir) 400 mg tablets ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login